Biomedical subjects

K Inada

Publications and source records attributed to K Inada.

310 records · Page 18Linked to original sources

PubMedDate not supplied

Treatment of endotoxemia with low-dose intramuscular injections or oral administration of polymyxin B.

Thirty patients with sepsis received 50,000 U of polymyxin B intramuscularly per day (n = 22) or 3 million U orally per day (n = 8). Plasma endotoxin levels were measured by the Endospecy test after treating the plasma with a new perchloric acid method. Plasma endotoxin levels were reduced to normal values (less than 9.8 pg/ml) in all the injected patients within two days and in all the orally treated patients within three days. Clinical symptoms were also ameliorated. No treatment side effects were reported. It is concluded that polymyxin B is a safe and effective treatment against endotoxemia.

Administration, Oral↗

PubMedDate not supplied

Inhibitory effects of ulinastatin on the production of cytokines: implications for the prevention of septicemic shock.

The study was designed to determine whether ulinastatin can be used as a biological response modifier for the prevention of septicemic shock. Monocytes from heparinized blood of three healthy volunteers were incubated with 0.125 or 1.25 U/ml of ulinastatin, and then endotoxin (Escherichia coli lipopolysaccharide) was added at concentrations of 0.1, 1.0, and 10.0 micrograms/ml. A dose-dependent increase in the production of tumor necrosis factor alpha, interleukin-1 alpha, and interleukin-1 beta was noted after endotoxin stimulation. Production of these cytokines was inhibited by the addition of ulinastatin in a dose-dependent manner. The results indicate that ulinastatin could be useful in the prevention of septicemic shock.

Cytokines↗

PubMedDate not supplied

Evaluation of IPM/CS in gram-negative bacillus infections: use of an endotoxin-specific assay.

The subjects were 26 patients hospitalized with severe trauma or burns. Twice daily for seven to 14 days, 1 gm of IPM/CS (a 1:1 combination of imipenem and cilastatin sodium) was administered by intravenous drip infusion to each patient. Clinical outcome was rated excellent in nine patients, good in 12, and fair in five. Bacteria, isolated in 21 of the 26 patients, were eliminated in 18 and decreased in three. Mean endotoxin levels, assessed by the Endospecy method, were reduced from 167.8 pg/ml before treatment to 5.1 pg/ml after treatment. No treatment side effects were noted.

Adult↗

PubMedDate not supplied

Levels of soluble adhesion molecules and cytokines in patients with septic multiple organ failure.

Multiple organ failure (MOF) is a common complication of sepsis or septic shock. In this condition, it is believed that activated neutrophils adhere to the vascular endothelium and induce various mediators and tissue damage, leading to organ damage. We investigated the plasma levels of inflammatory cytokine activating neutrophils, soluble adhesive molecules, and endotoxin in 8 patients with septic MOF, 15 patients with sepsis but without MOF, and in 5 patients with MOF unrelated infection. The soluble intercellular adhesion molecule-1 (sICAM-1) concentration in sepsis-complicated groups was significantly higher than that in the multiple organ failure (MOF) group without infection. Of sepsis-complicated groups, the sICAM-1 value in the MOF group was significantly higher than that in the sepsis group without MOF. In sepsis-complicated groups, both soluble endothelial-leukocyte adhesion molecule-1 (sELAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) concentrations were significantly higher than those in the MOF group without infection. However, there was no significant difference between the septic MOF group and the sepsis group without MOF. In patients showing high levels of soluble adhesion molecule, prognosis was poor, and the concentration of soluble adhesion molecules rapidly decreased during recovery from MOF. It is speculated that endotoxin and inflammatory cytokines damage vascular endothelium as well as various other cells and produce, a large number of adhesion molecule, especially in patients with septic MOF, causing leakage of adhesion molecules into blood.

Adult↗